Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement.
about
Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.The combination of laser Doppler perfusion imaging and photoplethysmography is useful in the characterization of scleroderma and primary Raynaud's phenomenon.Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis.Application of biomarkers to clinical trials in systemic sclerosis.Endothelin-1 activates ETA receptors to cause reflex scratching in BALB/c mice.Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in SclerodermaVasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis.Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertensionTranscriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells.Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1.Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice.Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis.Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities.Biomarkers in systemic sclerosis.Serum levels of soluble ICAM-1 in children with pulmonary artery hypertension.The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis.Circulating biomarkers of interstitial lung disease in systemic sclerosis.Facts and promises on lung biomarkers in interstitial lung diseases.Vasculopathy in scleroderma.Biomarkers in systemic sclerosis: Their potential to predict clinical courses.Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis.Circulating microparticles and plasma levels of soluble E- and P-selectins in patients with systemic sclerosis.Potential biomarkers in patients with systemic sclerosis.Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study.Elevated serum levels of soluble CD146 in patients with systemic sclerosis.Nailfold videocapillaroscopy results in patients with rheumatoid arthritis.Levels of Soluble Endothelium Adhesion Molecules and Complications among Sickle Cell Disease Patients in Ghana.A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic SclerosisClinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activityLinking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis
P2860
Q30825417-FACA13E5-301F-4F4A-A090-17BABC2BEE2CQ33825670-D242EC6D-334B-40E1-8BA1-70F99B8E3F0EQ35668241-8733A50B-E8F9-496B-AD22-19A46D42E2B0Q35681874-04F6DBC3-E082-480F-B02B-A3D492C3BEA6Q36052759-D90BFD5C-3B1B-4E19-B551-AB2148925428Q36289139-1C636510-9D95-4FF1-83FC-6AC543AB14E2Q36927749-0CD826B4-AEAE-4F32-B6CC-F670A2AA8F74Q36930652-39D4DBD1-7847-4DCB-A8B0-2D5400ED3CEEQ37034391-2FE2D8A0-81AC-47C9-8E9E-7AEB9AD95530Q37224668-CBD03E4A-0F4F-406C-A5B2-245E609866A1Q37226607-791A3236-9739-46AC-B7A1-E650110C7FF5Q37234373-1765C159-C7E6-4852-BD20-0ACF7816EA90Q37310583-2BEB2A71-6266-4F56-9AA6-C41994FB8AB7Q37395995-9D6C5A5D-FB02-4B23-8D76-69282B34DF49Q37730018-D44DEB0F-7A1F-435F-A9F9-83F9ECAB4DCDQ37731996-B6C7D807-65F5-4979-B408-1235FC83F387Q38042445-FAB48DFB-2FFB-4FAE-BCA9-9572DEC360A6Q38044387-6B913E6C-5B83-498C-B76A-2E33064E01E1Q38543042-EB6AE58E-CC07-4CBF-A259-D09A172401A4Q38543688-0689F7C3-9A2D-4F8D-BF6E-4327EC7BAC8CQ38701985-7E45BFED-2E21-4CB7-8AF7-5391B332124DQ39966988-C7BD74E4-939E-449B-8DA5-036DAF99F0E3Q45369141-A4B397C5-BDD1-4B14-80F0-7F1546CCDF7FQ46647964-F7399251-F5A1-48EB-9F5C-DFA9D2EA9C80Q47662284-B68A9C6A-79C4-4B55-ABAF-9BFB7C45063AQ50329525-863461F6-935C-47E5-8A78-8E4F22A8E0ECQ51140742-3F8F8FF9-007F-4F27-8A4C-96076B0EA063Q54522497-0BC47FEC-08F1-4BD1-9738-E6CBCB1391B7Q55445797-4E10AF1D-4B0C-4EDA-A0F2-39A63DE24A27Q57072741-92B6F4BF-3760-4B3D-BD75-49966C688534Q58484335-1BA5036D-9549-4CB0-AFDB-A9EEC4A54437Q58762092-0AA9C142-2EBF-4DE9-B79F-09F9B4EA68C5
P2860
Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Soluble adhesion molecules (sV ...... to organ systemic involvement.
@en
Soluble adhesion molecules (sV ...... to organ systemic involvement.
@nl
type
label
Soluble adhesion molecules (sV ...... to organ systemic involvement.
@en
Soluble adhesion molecules (sV ...... to organ systemic involvement.
@nl
prefLabel
Soluble adhesion molecules (sV ...... to organ systemic involvement.
@en
Soluble adhesion molecules (sV ...... to organ systemic involvement.
@nl
P1476
Soluble adhesion molecules (sV ...... to organ systemic involvement
@en
P2093
Stanislaw Sierakowski
P304
P356
10.1007/S10067-004-0987-3
P577
2004-09-03T00:00:00Z